---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-099094"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:51:19.369879+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OS Therapies Q3 net loss $2.9M; Phase 2b osteosarcoma data due Dec 2024

## Summary
- Net operating loss $2.875M in Q3 2024 vs $2.006M in Q3 2023; EPS -$0.18 vs -$0.38.
- Completed dosing all 41 patients in Phase 2b trial of OST-HER2 in resected recurrent osteosarcoma.
- Topline Phase 2b data expected December 2024; seeking FDA Breakthrough Therapy designation.
- Company completed IPO in Q3 2024; pre-revenue with future revenue expected from priority review voucher.

## SEC filing metadata
- accession: 0001213900-24-099094
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/0001213900-24-099094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/ea0221417-8k_osthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-099094
- JSON: https://secwatch.observer/filing/0001213900-24-099094.json
- Plain text: https://secwatch.observer/filing/0001213900-24-099094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.